Free DNA and P53 Antibodies in Ovarian Cancers
Free DNA and P53 Antibodies in Ovarian Cancers
Background: This study was conducted in order to evaluate the significance of circulating free DNA (CFDNA), blood plasma p53 antibodies (p53-Ab) and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.
Patients and methods: A total of 126 patients were included in this study. KRAS mutations and CFDNA were detected by means of the PCR–restriction fragment length polymorphism (PCR-RFLP) and enriched by the PCR-RFLP method. Enzyme-linked immunosorbent assay was used to analyze plasma p53-Ab.
Results:KRAS mutations were detected in 27 (21.4%) of examined tumors. The frequency of KRAS mutations was especially high in mucinous cancers (P < 0.001). CFDNA and p53-Ab were frequently detected in patients with serous cancers in high grade (P < 0.001). The overall survival rate was significantly lower for patients with serous tumors and CFDNA and p53-Ab-positive than negative tumors (P = 0.022 and P < 0.001, respectively). In mucinous ovarian cancer, a worse overall survival was correlated with the KRAS mutations (P = 0.03).
Conclusions: The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression.
Epithelial ovarian cancer comprises the majority of malignant ovarian tumors in adult women. About 190 000 new cases and 114 000 deaths from ovarian cancer are estimated to occur annually. The highest rates are reported in Scandinavia and Eastern Europe, the United States and Canada. The age-adjusted incidence rate in the United States is 12.48 per 100 000 women per year. Low rates are found in Africa and Asia. In Poland, the age-adjusted incidence is 10.8 per 100 000 women per year. The overall 5-year survival rate for all stages combined range from 30%/INS< to 50%. Most women, however, present with late-stage disease, which is associated with a rate of about 20%.
Activation of protooncogenes is a feature of many malignancies and, not surprisingly, there have been numerous searches for oncogene mutations as well as for specific genes dysregulation involved in apoptotic, neoangiogenetic and transduction signal pathways. In ovarian cancer, KRAS mutations are seen in 4%–30% of cases.TP53 mutations have been found in 50% of cases. The frequencies of p53 antibodies (p53-Ab) in serum vary from 8% to 46%. Several methods have been used for circulating free DNA (CFDNA) quantification, but none have been evaluated in terms of reproducibility and therefore, results from different studies are not comparable.
This study was conducted in order to evaluate the significance of CFDNA, blood plasma p53-Ab and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.
Abstract and Introduction
Abstract
Background: This study was conducted in order to evaluate the significance of circulating free DNA (CFDNA), blood plasma p53 antibodies (p53-Ab) and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.
Patients and methods: A total of 126 patients were included in this study. KRAS mutations and CFDNA were detected by means of the PCR–restriction fragment length polymorphism (PCR-RFLP) and enriched by the PCR-RFLP method. Enzyme-linked immunosorbent assay was used to analyze plasma p53-Ab.
Results:KRAS mutations were detected in 27 (21.4%) of examined tumors. The frequency of KRAS mutations was especially high in mucinous cancers (P < 0.001). CFDNA and p53-Ab were frequently detected in patients with serous cancers in high grade (P < 0.001). The overall survival rate was significantly lower for patients with serous tumors and CFDNA and p53-Ab-positive than negative tumors (P = 0.022 and P < 0.001, respectively). In mucinous ovarian cancer, a worse overall survival was correlated with the KRAS mutations (P = 0.03).
Conclusions: The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression.
Introduction
Epithelial ovarian cancer comprises the majority of malignant ovarian tumors in adult women. About 190 000 new cases and 114 000 deaths from ovarian cancer are estimated to occur annually. The highest rates are reported in Scandinavia and Eastern Europe, the United States and Canada. The age-adjusted incidence rate in the United States is 12.48 per 100 000 women per year. Low rates are found in Africa and Asia. In Poland, the age-adjusted incidence is 10.8 per 100 000 women per year. The overall 5-year survival rate for all stages combined range from 30%/INS< to 50%. Most women, however, present with late-stage disease, which is associated with a rate of about 20%.
Activation of protooncogenes is a feature of many malignancies and, not surprisingly, there have been numerous searches for oncogene mutations as well as for specific genes dysregulation involved in apoptotic, neoangiogenetic and transduction signal pathways. In ovarian cancer, KRAS mutations are seen in 4%–30% of cases.TP53 mutations have been found in 50% of cases. The frequencies of p53 antibodies (p53-Ab) in serum vary from 8% to 46%. Several methods have been used for circulating free DNA (CFDNA) quantification, but none have been evaluated in terms of reproducibility and therefore, results from different studies are not comparable.
This study was conducted in order to evaluate the significance of CFDNA, blood plasma p53-Ab and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.
